High-resolution melting analysis is a more effective approach for screening TSC genes mutations

Tz Shiu Tsai, Mu Yi Huang, Yu Tsui Chang, Chuan Yu Wang, Ju Li Lin, Po Cheng Hung, Shuan Pei Lin, Chien Feng Sun, Wei Shun Wang, Chung Ming Chang, Shih Cheng Chang, Da Chang Chu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder with a prevalence of 1 in 95,136 in Taiwan. TSC is characterized by hamartomatous lesions in multiple organ systems. Genetic defects in TSC1 and TSC2 genes are the main causes of TSC. A molecular screening protocol using denaturing high-performance liquid chromatography (dHPLC) followed by DNA sequencing is currently performed to locate the genetic lesions in many clinical laboratories. The current screening approach is time consuming and inefficient. In this study, we analyzed all coding exons of TSC1 and TSC2 genes of 30 TSC patients and 47 unaffected family members using the traditional dHPLC protocol and our recently developed diagnostic platform based on high-resolution melting analysis (HRM) followed by bidirectional DNA sequencing. Data indicated that 20 mutations, including 5 mutations in TSC1 (2 sporadic, 1 familial mutation, and 2 of uncertain origin) and 15 mutations in TSC2 (14 sporadic and 1 familial mutation), 8 single-nucleotide polymorphisms (SNPs, including 3 SNPs found in irrelevant individuals without TSC phenotypes studied in the control group), and 3 variants with undetermined significance were identified, including 4 novel mutations. The sensitivities of HRM and dHPLC for TSC mutation screening were estimated as 95% and 75%, respectively. The specificities of HRM and dHPLC for TSC mutation screening were evaluated as 91% and 98%. In addition, results suggested our novel HRM screening protocol to be more economical. In conclusion, we successfully developed a superior approach for TSC genes mutation screening for clinical application.

Original languageEnglish
Pages (from-to)415-421
Number of pages7
JournalGenetic Testing and Molecular Biomarkers
Volume15
Issue number6
DOIs
Publication statusPublished - Jun 1 2011
Externally publishedYes

Fingerprint

Tuberous Sclerosis
Freezing
Mutation
Genes
High Pressure Liquid Chromatography
Single Nucleotide Polymorphism
DNA Sequence Analysis
Taiwan
Exons
Phenotype
Control Groups

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Tsai, T. S., Huang, M. Y., Chang, Y. T., Wang, C. Y., Lin, J. L., Hung, P. C., ... Chu, D. C. (2011). High-resolution melting analysis is a more effective approach for screening TSC genes mutations. Genetic Testing and Molecular Biomarkers, 15(6), 415-421. https://doi.org/10.1089/gtmb.2010.0133

High-resolution melting analysis is a more effective approach for screening TSC genes mutations. / Tsai, Tz Shiu; Huang, Mu Yi; Chang, Yu Tsui; Wang, Chuan Yu; Lin, Ju Li; Hung, Po Cheng; Lin, Shuan Pei; Sun, Chien Feng; Wang, Wei Shun; Chang, Chung Ming; Chang, Shih Cheng; Chu, Da Chang.

In: Genetic Testing and Molecular Biomarkers, Vol. 15, No. 6, 01.06.2011, p. 415-421.

Research output: Contribution to journalArticle

Tsai, TS, Huang, MY, Chang, YT, Wang, CY, Lin, JL, Hung, PC, Lin, SP, Sun, CF, Wang, WS, Chang, CM, Chang, SC & Chu, DC 2011, 'High-resolution melting analysis is a more effective approach for screening TSC genes mutations', Genetic Testing and Molecular Biomarkers, vol. 15, no. 6, pp. 415-421. https://doi.org/10.1089/gtmb.2010.0133
Tsai, Tz Shiu ; Huang, Mu Yi ; Chang, Yu Tsui ; Wang, Chuan Yu ; Lin, Ju Li ; Hung, Po Cheng ; Lin, Shuan Pei ; Sun, Chien Feng ; Wang, Wei Shun ; Chang, Chung Ming ; Chang, Shih Cheng ; Chu, Da Chang. / High-resolution melting analysis is a more effective approach for screening TSC genes mutations. In: Genetic Testing and Molecular Biomarkers. 2011 ; Vol. 15, No. 6. pp. 415-421.
@article{d4f485b038cd484cb12064afd922c6b7,
title = "High-resolution melting analysis is a more effective approach for screening TSC genes mutations",
abstract = "Tuberous sclerosis complex (TSC) is an autosomal dominant disorder with a prevalence of 1 in 95,136 in Taiwan. TSC is characterized by hamartomatous lesions in multiple organ systems. Genetic defects in TSC1 and TSC2 genes are the main causes of TSC. A molecular screening protocol using denaturing high-performance liquid chromatography (dHPLC) followed by DNA sequencing is currently performed to locate the genetic lesions in many clinical laboratories. The current screening approach is time consuming and inefficient. In this study, we analyzed all coding exons of TSC1 and TSC2 genes of 30 TSC patients and 47 unaffected family members using the traditional dHPLC protocol and our recently developed diagnostic platform based on high-resolution melting analysis (HRM) followed by bidirectional DNA sequencing. Data indicated that 20 mutations, including 5 mutations in TSC1 (2 sporadic, 1 familial mutation, and 2 of uncertain origin) and 15 mutations in TSC2 (14 sporadic and 1 familial mutation), 8 single-nucleotide polymorphisms (SNPs, including 3 SNPs found in irrelevant individuals without TSC phenotypes studied in the control group), and 3 variants with undetermined significance were identified, including 4 novel mutations. The sensitivities of HRM and dHPLC for TSC mutation screening were estimated as 95{\%} and 75{\%}, respectively. The specificities of HRM and dHPLC for TSC mutation screening were evaluated as 91{\%} and 98{\%}. In addition, results suggested our novel HRM screening protocol to be more economical. In conclusion, we successfully developed a superior approach for TSC genes mutation screening for clinical application.",
author = "Tsai, {Tz Shiu} and Huang, {Mu Yi} and Chang, {Yu Tsui} and Wang, {Chuan Yu} and Lin, {Ju Li} and Hung, {Po Cheng} and Lin, {Shuan Pei} and Sun, {Chien Feng} and Wang, {Wei Shun} and Chang, {Chung Ming} and Chang, {Shih Cheng} and Chu, {Da Chang}",
year = "2011",
month = "6",
day = "1",
doi = "10.1089/gtmb.2010.0133",
language = "English",
volume = "15",
pages = "415--421",
journal = "Genetic Testing and Molecular Biomarkers",
issn = "1945-0265",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - High-resolution melting analysis is a more effective approach for screening TSC genes mutations

AU - Tsai, Tz Shiu

AU - Huang, Mu Yi

AU - Chang, Yu Tsui

AU - Wang, Chuan Yu

AU - Lin, Ju Li

AU - Hung, Po Cheng

AU - Lin, Shuan Pei

AU - Sun, Chien Feng

AU - Wang, Wei Shun

AU - Chang, Chung Ming

AU - Chang, Shih Cheng

AU - Chu, Da Chang

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Tuberous sclerosis complex (TSC) is an autosomal dominant disorder with a prevalence of 1 in 95,136 in Taiwan. TSC is characterized by hamartomatous lesions in multiple organ systems. Genetic defects in TSC1 and TSC2 genes are the main causes of TSC. A molecular screening protocol using denaturing high-performance liquid chromatography (dHPLC) followed by DNA sequencing is currently performed to locate the genetic lesions in many clinical laboratories. The current screening approach is time consuming and inefficient. In this study, we analyzed all coding exons of TSC1 and TSC2 genes of 30 TSC patients and 47 unaffected family members using the traditional dHPLC protocol and our recently developed diagnostic platform based on high-resolution melting analysis (HRM) followed by bidirectional DNA sequencing. Data indicated that 20 mutations, including 5 mutations in TSC1 (2 sporadic, 1 familial mutation, and 2 of uncertain origin) and 15 mutations in TSC2 (14 sporadic and 1 familial mutation), 8 single-nucleotide polymorphisms (SNPs, including 3 SNPs found in irrelevant individuals without TSC phenotypes studied in the control group), and 3 variants with undetermined significance were identified, including 4 novel mutations. The sensitivities of HRM and dHPLC for TSC mutation screening were estimated as 95% and 75%, respectively. The specificities of HRM and dHPLC for TSC mutation screening were evaluated as 91% and 98%. In addition, results suggested our novel HRM screening protocol to be more economical. In conclusion, we successfully developed a superior approach for TSC genes mutation screening for clinical application.

AB - Tuberous sclerosis complex (TSC) is an autosomal dominant disorder with a prevalence of 1 in 95,136 in Taiwan. TSC is characterized by hamartomatous lesions in multiple organ systems. Genetic defects in TSC1 and TSC2 genes are the main causes of TSC. A molecular screening protocol using denaturing high-performance liquid chromatography (dHPLC) followed by DNA sequencing is currently performed to locate the genetic lesions in many clinical laboratories. The current screening approach is time consuming and inefficient. In this study, we analyzed all coding exons of TSC1 and TSC2 genes of 30 TSC patients and 47 unaffected family members using the traditional dHPLC protocol and our recently developed diagnostic platform based on high-resolution melting analysis (HRM) followed by bidirectional DNA sequencing. Data indicated that 20 mutations, including 5 mutations in TSC1 (2 sporadic, 1 familial mutation, and 2 of uncertain origin) and 15 mutations in TSC2 (14 sporadic and 1 familial mutation), 8 single-nucleotide polymorphisms (SNPs, including 3 SNPs found in irrelevant individuals without TSC phenotypes studied in the control group), and 3 variants with undetermined significance were identified, including 4 novel mutations. The sensitivities of HRM and dHPLC for TSC mutation screening were estimated as 95% and 75%, respectively. The specificities of HRM and dHPLC for TSC mutation screening were evaluated as 91% and 98%. In addition, results suggested our novel HRM screening protocol to be more economical. In conclusion, we successfully developed a superior approach for TSC genes mutation screening for clinical application.

UR - http://www.scopus.com/inward/record.url?scp=79959215369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959215369&partnerID=8YFLogxK

U2 - 10.1089/gtmb.2010.0133

DO - 10.1089/gtmb.2010.0133

M3 - Article

C2 - 21510812

AN - SCOPUS:79959215369

VL - 15

SP - 415

EP - 421

JO - Genetic Testing and Molecular Biomarkers

JF - Genetic Testing and Molecular Biomarkers

SN - 1945-0265

IS - 6

ER -